Trial | NCT03385135  Report issue

Title

Allopurinol and Endothelial Function in Diabetic CAD Patients
Impact of ALLopurInol on Endothelial fuNCtion in diabEtic Patients Affected With Coronary Artery Disease

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Study Participants

    58
This is a randomized trial assessing the impact of allopurinol on endothelial function in optimally treated diabetic patients with coronary artery disease. After initial screening, subjects were randomized to receive either optimal medical therapy (OMT) + allopurinol or OMT alone for 8 weeks. The dose of allopurinol was 300 mg for 4 weeks and 600 mg for 4 weeks with a 4-weekly check on hematology and biochemistry
Study Started
Dec 31
2017
Anticipated
Primary Completion
Mar 31
2018
Anticipated
Study Completion
Jun 30
2018
Anticipated
Last Update
Dec 28
2017

Drug Allopurinol

300 mg for 4 weeks then 600 mg for 4 weeks in the active group

  • Other names: Optimal Medical Therapy

Allopurinol group Active Comparator

Optimal medical therapy associated with allopurinol. The dose of allopurinol is 300 mg for 4 weeks then 600 mg for 4 weeks

No Allopurinol group No Intervention

Optimal medical therapy alone

Criteria 

Inclusion Criteria:

Diabetes type 2
Known coronary artery disease with previous percutaneous coronary intervention and optimal medical therapy for at least one month

Exclusion Criteria:

Pregnant or breast- feeding women
creatinine clearance <60ml/min
Known history of gout disease or ongoing treatment with allopurinol
Allergy to allopurinol
Inability to provide informed consent
No Results Posted